Ang II type 1 receptor (AT1R) blockers (ARBs) have been reported to be useful in diminishing cognitive deficits linked to Post-Stroke Cognitive Impairment (PSCI), Alzheimer’s Disease, Parkinson’s Disease, and Vascular Cognitive Impairment (VCI) [16]. Here, AGTR1 is linked to Cognitive impairment.